Clinical Trial Update: Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating adjuvant nivolumab with low-dose ipilimumab in stage III melanoma and resected stage IV melanoma have been posted (results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Brown University | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-03-22